 |
|
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia
Miranda H. Chakos, MD;
Jose Ma. J. Alvir, DrPH;
Margaret G. Woerner, PhD;
Amy Koreen, MD;
Stephen Geisler, MD;
David Mayerhoff, MD;
Steven Sobel, MD;
John M. Kane, MD;
Michael Borenstein, PhD;
Jeffrey A. Lieberman, MD
Arch Gen Psychiatry. 1996;53(4):313-319.
Abstract
Background
There is controversy over whether tardive dyskinesia (TD) is solely a consequence of antipsychotic drug treatment or in part may reflect an intrinsic aspect of the disease process. Pathophysiologic factors could, independently or in concert with drug effects, lead to the development of dyskinetic signs.
Methods
We studied prospectively 118 patients in their first episode of psychosis who were treatment-naive or had less than 12 weeks of antipsychotic drug exposure at study entry. Patients received standardized antipsychotic drug treatment and were evaluated for up to 81/2 years with regular assessments of psychopathologic signs and symptoms and side effects.
Results
The cumulative incidence of presumptive TD was 6.3% after 1 year of follow-up, 11.5% after 2 years, 13.7% after 3 years, and 17.5% after 4 years. Persistent TD had a cumulative incidence of 4.8% after 1 year, 7.2% after 2 years, and 15.6% after 4 years. Taken individually, both antipsychotic drug dose, entered as a time-dependent covariate, and poor response to treatment of the first psychotic episode were significant predicters of time to TD. When antipsychotic drug dose and treatment response were examined together, treatment responders had significantly lower hazards for presumptive TD than nonresponders (hazard ratio, 0.29; 95% confidence interval, 0.09 to 0.97). Dose was a trend-level predicter, with each 100-mg chlorpromazine equivalent unit increase in dose associated with a 5% increase in the hazard of presumptive TD (hazard ratio, 1.05; 95% confidence interval, 0.99 to 1.11).
Conclusion
Poor response to the treatment of a first episode of psychosis and, to a lesser extent, antipsychotic drug dose are important factors in the development of TD. This suggests that there may be a disease-related vulnerability to TD manifest with antipsychotic drug exposure. Potential pathophysiologic factors might include neurodevelopmentally induced structural neuropathologic characteristics, sensitization of nigrostriatal dopamine neurons, and the induction of glutamatergically mediated neurotoxic effects.
Author Affiliations
From the Department of Psychiatry, Hillside Hospital, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY. Dr Lieberman is now with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia
Tenback et al.
J Psychopharmacol 2010;24:1031-1035.
ABSTRACT
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study
Kelly et al.
J Psychopharmacol 2009;23:436-441.
ABSTRACT
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller et al.
Br. J. Psychiatry 2008;193:279-288.
ABSTRACT
| FULL TEXT
Drug-Induced Movement Disorders
Claxton et al.
Journal of Pharmacy Practice 2007;20:415-429.
ABSTRACT
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics
Rosenheck
Br. J. Psychiatry 2007;191:238-245.
ABSTRACT
| FULL TEXT
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial
Keefe et al.
Arch Gen Psychiatry 2007;64:633-647.
ABSTRACT
| FULL TEXT
Pharmacological Treatments for First-Episode Schizophrenia
Robinson et al.
Schizophr Bull 2005;31:705-722.
ABSTRACT
| FULL TEXT
Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness
Honer et al.
J Psychopharmacol 2005;19:277-285.
ABSTRACT
Low dose typical antipsychotics - a brief evaluation
Taylor
The Psychiatrist 2000;24:465-468.
FULL TEXT
The Current Status of Tardive Dyskinesia
Sachdev
Aust N Z J Psychiatry 2000;34:355-369.
ABSTRACT
| FULL TEXT
Tardive dyskinesia was associated with poor treatment response and higher antipsychotic drug dose after the first episode of schizophrenia
Evid. Based Med. 1996;1:186-186.
Who Gets Tardive Dyskinesia?
JWatch Psychiatry 1996;1996:9-9.
FULL TEXT
|
